C

LEVELAND — Facing annual spikes in pharmaceutical costs, major hospitals nationwide are curtailing use of expensive drugs and rejecting new additions to their formularies, sometimes triggering tense debates with clinicians who want to offer cutting-edge medications to their patients.

The conflict, involving a wide array of drugs, is bound to become more intense amid the specter of a GOP-led health care overhaul that could further undermine hospital finances. Already, hospitals are cutting down on use of certain pain medications and carefully scrutinizing requests to add expensive new drugs to treat conditions ranging from epilepsy to cancer.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • We have a policy pricing disconnect between patented high priced marginal efficacy drugs and underpriced generic injectables no longer manufactured in the USA, in shortage and with rapidly escalating prices. Time for President Trump, negotiator in chief, to bring big PHARMA to the table along with GPOs that are anti-kickback antitrust immune and tell them that the party is over. Either manufacture generics in USA in abundant supply so that pricing power for innovation is preserved or face governmental negotiation of prices for innovative drugs.

Recommended Stories

Sign up for our
Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine — delivered straight to your inbox every weekday afternoon.